Curanex Pharmaceuticals Inc (NASDAQ:CURX) Sees Large Decrease in Short Interest

Curanex Pharmaceuticals Inc (NASDAQ:CURX) saw a significant drop in short interest during the month of June. As of June 30th, there was short interest totaling 20,835 shares, a drop of 38.0% from the June 15th total of 33,610 shares. Approximately 0.1% of the company’s shares are sold short. Based on an average daily trading volume, of 77,001 shares, the days-to-cover ratio is currently 0.3 days.

Institutional Investors Weigh In On Curanex Pharmaceuticals

An institutional investor recently bought a new stake in Curanex Pharmaceuticals stock. Citadel Advisors LLC acquired a new stake in Curanex Pharmaceuticals Inc (NASDAQ:CURX) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 64,067 shares of the company’s stock, valued at approximately $46,000.

Curanex Pharmaceuticals Stock Down 5.7%

Curanex Pharmaceuticals stock traded down $0.01 during midday trading on Friday, reaching $0.21. The stock had a trading volume of 16,196 shares, compared to its average volume of 67,539. Curanex Pharmaceuticals has a 52-week low of $0.20 and a 52-week high of $9.18. The firm has a market cap of $5.83 million and a price-to-earnings ratio of -0.76. The company has a fifty day moving average of $0.29 and a 200 day moving average of $0.35.

Curanex Pharmaceuticals (NASDAQ:CURX) last announced its earnings results on Thursday, May 14th. The company reported ($0.11) earnings per share (EPS) for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of Curanex Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Curanex Pharmaceuticals Company Profile

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.